PSP is currently in the animal-testing phase of research in many countries for use as an anti-tumor drug.
It appears to work as a biological response modifier (BRM), enhancing the body's own use of macrophages and T-lymphocytes, rather than directly attacking any tumors.
Each compound has shown remarkable anticancer properties with few side effects.
[2] By 1987 PSK accounted for more than 25% of total national expenditure for anticancer agents in Japan.
This antineoplastic or immunomodulatory drug article is a stub.